Search

Your search keyword '"G. Fournier"' showing total 7 results
Start Over Author "G. Fournier" Search Limiters Peer Reviewed
7 results on '"G. Fournier"'

1. Robot-assisted artificial urinary sphincter implantation in female patients: An international multicenter study

Author

B. Peyronnet, G. Capon, X. Biardeau, O. Belas, P. Lecoanet, L. Castro-Sader, M. Allue, R. Hein, M. Daher, A. Manunta, G. Robert, J. Hascoet, F. Dubois, F. Thibault, V. Cardot, A. Vidart, A. Descazeaud, G. Fournier, W. Everaerts, and F. Van Der Aa

Subjects
Diseases of the genitourinary system. Urology, RC870-923, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Published
2020
Full Text
View/download PDF

2. Laparoscopic adrenalectomy for adrenal metastasis: Comparison of the transperitoneal vs. retroperitoneal approaches

Author

A. Goujon, N. Schoentgen, R. Betari, A. Gryn, V. Vanalderwerelt, S. Oumakhlouf, M. Toulouzan, N. Brichart, B. Pradere, M. Soulie, G. Fournier, F. Saint, K. Bensalah, F. Bruyere, V. Joulin, F. Nouhaud, E. Huygue, A. Manunta, and B. Peyronnet

Subjects
Diseases of the genitourinary system. Urology, RC870-923, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Published
2020
Full Text
View/download PDF

3. Prognostic factors after adrenalectomy for adrenal metastasis

Author

A. Goujon, N. Schoentgen, R. Betari, M. Thoulouzan, V. Vanalderwerelt, S. Oumakhlouf, N. Brichart, B. Pradere, M. Roumiguie, A. Rammal, K. Bensalah, G. Fournier, F. Bruyere, P. Grise, V. Joulin, A. Manunta, F. Saint, E. Huyghe, F. Nouhaud, and B. Peyronnet

Subjects
Diseases of the genitourinary system. Urology, RC870-923, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Published
2020
Full Text
View/download PDF

4. External validation of the new Briganti nomogram predicting lymph node invasion in patients with intermediate and high-risk prostate cancer: Results from a multicentric European cohort

Author

R. Diamand, S. Albisinni, A. Fourcade, G. Fournier, D. Benamran, G. Fiard, J.L. Descotes, G. Assenmacher, I. Svistakov, A. Peltier, G. Simone, G. Di Cosmo, J.B. Roche, J.L. Bonnal, J. Van Damme, M. Rossi, E. Mandron, M. Oderda, and T. Roumeguere

Subjects
Diseases of the genitourinary system. Urology, RC870-923, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Published
2020
Full Text
View/download PDF

5. How Do Bisphosphonates Inhibit Bone Metastasis In Vivo

Author

Pierrick G. Fournier, Verena Stresing, Frank H. Ebetino, and Philippe Clezardin

Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Bisphosphonates are potent inhibitors of osteoclast-mediated bone resorption and have demonstrated clinical utility in the treatment of patients with osteolytic bone metastases. They also exhibit direct antitumor activity in vitro and can reduce skeletal tumor burden and inhibit the formation of bone metastases in vivo. However, whether such effects are caused by a direct action of bisphosphonates on tumor cells or indirectly through inhibition of bone resorption remains unclear. To address this question, we used here a structural analog of the bisphosphorate risedronate, NE-58051, which has a bone mineral affinity similar to that of risedronate, but a 3000-fold lower bone antiresorptive activity. In vitro, risedronate and NE-58051 inhibited proliferation of breast cancer and melanoma cell lines. In vivo, risedronate and NE-58051 did not inhibit the growth of subcutaneous B02 breast tumor xenografts or the formation of B16F10 melanoma lung metastasis. In contrast to NE-58051, risedronate did inhibit B02 breast cancer bone metastasis formation by reducing both bone destruction and skeletal tumor burden, indicating that the antitumor effect of bisphosphonates is achieved mainly through inhibition of osteoclast-mediated bone resorption.

Published
2010
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results